Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Treatment Clinical Trials for Chronic Myelogenous Leukemia (CML)

Review the chronic myelogenous leukemia (cml) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 58

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Status: Active
Location: 21 locations
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Status: Active
Location: 12 locations
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Status: Active
Location: 20 locations
CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
Status: Active
Location: 8 locations
A Study of 131-I Apamistamab and CAR T-cell Therapy in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Status: Active
Location: 7 locations
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Status: Active
Location: 6 locations
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Active
Location: 5 locations
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Status: Active
Location: 4 locations
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Status: Active
Location: 5 locations
Inotuzumab Ozogamicin in Treating Patients with Acute Lymphocytic Leukemia after Transplant
Status: Active
Location: 4 locations
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 4 locations
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Status: Active
Location: 5 locations
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Status: Active
Location: 5 locations
ASCIMINIB, Dasatinib, Prednisone, and Blinatumomab in Treating Patients with BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, or Chronic Myeloid Leukemia
Status: Active
Location: 4 locations
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Status: Active
Location: 4 locations
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Status: Active
Location: 3 locations
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Status: Active
Location: 3 locations
Orca Q Stem Cells for the Treatment of Pediatric Patients with Leukemia
Status: Active
Location: 4 locations
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Status: Active
Location: 3 locations
Tyrosine Kinase Inhibitor Cessation for Chronic Myeloid Leukemia Patients With Stable Molecular Response
Status: Active
Location: 2 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 5 locations
Donor Partial Immune Cell Depletion for the Treatment of Hematologic Malignancies
Status: Active
Location: 2 locations
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
Status: Active
Location: 3 locations
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas